The field of cellular immunotherapy for cancer has experienced exponential growth over the
last decade. Several chimeric antigen receptor T cell products have already received FDA
approval, which has stimulated growth and enthusiasm for other cellular therapies.
Preclinical models are critical steps in the development of these products, and
understanding their in vivo trafficking and persistence are critical components of their
efficacy and toxicity analogous to volume of distribution and tissue penetration in small …